Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc.

ADXS
Ayala Pharmaceuticals, Inc.US flagOther OTC
0.60
USD
- -
- -
25.71MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
0.27
0.38
0.24
0.24
- -
0.1
Basic EPS, GAAP
-1.31
-2.07
-3.06
-2.8
-13.13
-7.99
-5.4
Free Cash Flow per Basic Share
-0.97
-1.9
-2.8
-2.66
-11.92
-4.9
-4.91
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3.38
-4.74
-7.18
-7.71
-51.52
-32.76
-21.23
Tangible Book Value per Share
-3.23
-4.54
3.89
2.37
-0.38
-5.45
-0.16
Basic Weighted Avg Shares
7
9
10
14
3
6
7
Sales/Revenue/Turnover
- -
2
4
4
1
- -
1
Operating Margin (%)
- -
-758.83
-803.05
-1,118.6
-5,419.51
-278,969.23
-5,421.1
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-9
-18
-30
-40
-38
-48
-38
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-762.3
-813
-1,148.15
-5,493.21
-369,784.62
-5,478.03
Working Capital
24
12
37
33
-3
-17
-3
LT Debt
- -
- -
1
- -
1
8
1
Total Equity
-22
-39
38
34
-1
-24
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Jun'22
Sep'22
Dec'22
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
15
Market Capitalization
35
15
8

Working Capital

FRC

in mil. unless spec.
Jun'22
Sep'22
Dec'22
Total Current Assets
23
13
3
Cash, Cash Equivalents & STI
20
11
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
6
6
Payables & Accruals
6
6
6
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
377.38%
2,121.75%
Free Cash Flow
- -
46.18%
-14.56%
Net Income, GAAP
- -
44.88%
26.46%
Sales/Revenue/Turnover
- -
- -
-98.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
1
1
1
1
4
2022
- -
- -
- -
- -
1
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.74
-0.75
-0.68
- -
-2.8
2022
-0.66
-2.83
-3.51
- -
-13.13
2023
-1.82
-1.53
- -
- -
-7.99

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Kenneth A. Berlin
Full Time Employees
20
Sector
Healthcare
Industry
Biotechnology
Address
9 Deer Park Drive Monmouth Junction NJ United States of America 08852
IPO Date
May 8, 2020
Business
Ayala Pharmaceuticals, Inc. (Ticker: ADXS) is a clinical-stage biopharmaceutical company primarily engaged in developing novel immunotherapies targeting cancer and infectious diseases. The company focuses on the design, manufacture, and commercialization of therapeutic vaccines and immunotherapies aimed at enhancing the immune system’s ability to fight diseased cells. Its core product pipeline includes ADXS-NEO, ADXS-HOT, and other Listeria-based immunotherapies for oncology indications such as cervical cancer, head and neck cancer, and HPV-related malignancies. Ayala Pharmaceuticals provides investigational biologic agents and related clinical development services targeted at oncologists and healthcare professionals globally. Founded in 2004 and headquartered in San Diego, California, Ayala Pharmaceuticals operates in the biotechnology and healthcare sectors with research, development, and commercialization activities primarily in the United States and select international markets. The company’s platform leverages proprietary Listeria monocytogenes-based technology to stimulate durable immune responses. In recent developments over the last 1-2 years, Ayala Pharmaceuticals has advanced its clinical pipeline with new trials and expanded strategic collaborations in immuno-oncology. It has focused on broadening indications for its lead therapeutic candidates and initiated partnerships to enhance clinical development and market reach. The company continues to build on its innovative pipeline by progressing multiple Phase 2 and Phase 3 trials, reflecting a strategic shift toward late-stage development and potential commercial readiness. Overall, Ayala Pharmaceuticals combines proprietary immunotherapy technology platforms with clinical and regulatory expertise to address significant unmet needs in oncology and infectious diseases, aiming for global impacts in cancer treatment. It remains publicly traded under the ticker ADXS, maintaining its operational and research headquarters in San Diego. This description integrates core products and services with the latest company advancements and contextual business information as typically found in financial data provider profiles.

Company News

APIChat
  • Aadi Bioscience (NASDAQ:AADI) and Ayala Pharmaceuticals (NASDAQ:ADXS) Head to Head Analysis

  • Head-To-Head Survey: Evofem Biosciences (NASDAQ:EVFM) and Ayala Pharmaceuticals (NASDAQ:ADXS)

  • OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

  • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline

  • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

  • Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

  • Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

  • Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

  • Ayala Pharmaceuticals Announces Closing of Merger with Biosight

  • Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

  • Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

  • Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

  • Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

  • OTC Markets Group Welcomes Advaxis, Inc. to OTCQX

  • 3 Hot Penny Stocks That Retail Traders Are Watching Right Now

  • Top Penny Stocks to Buy From TikTok? 3 That Investors Are Watching

  • 6 of the Hottest Stocks to Pick Up for Less Than $1

  • Best Penny Stocks to Buy Next Month? 3 You Need to Know About

  • Top Trending Penny Stocks to Watch Next Month

  • 3 Trending Penny Stocks For Your Small-Caps Watchlist Right Now